Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Other Non-Current Liabilities: 2019-2025

  • Burning Rock Biotech's Other Non-Current Liabilities was N/A to $10.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.9 million, marking a year-over-year change of. This contributed to the annual value of $1.4 million for FY2024, which is 123.82% up from last year.
  • Burning Rock Biotech's Other Non-Current Liabilities amounted to $10.9 million in Q2 2025, which was up 662.89% from $1.4 million recorded in Q4 2024.
  • Burning Rock Biotech's Other Non-Current Liabilities' 5-year high stood at $10.9 million during Q2 2025, with a 5-year trough of $598,000 in Q4 2022.
  • Moreover, its 3-year median value for Other Non-Current Liabilities was $1.4 million (2024), whereas its average is $4.3 million.
  • As far as peak fluctuations go, Burning Rock Biotech's Other Non-Current Liabilities skyrocketed by 5,180.00% in 2021, and later crashed by 67.64% in 2022.
  • Burning Rock Biotech's Other Non-Current Liabilities (Quarterly) stood at $1.8 million in 2021, then slumped by 67.64% to $598,000 in 2022, then climbed by 6.69% to $638,000 in 2023, then soared by 123.82% to $1.4 million in 2024, then reached $10.9 million in 2025.
  • Its Other Non-Current Liabilities was $10.9 million in Q2 2025, compared to $1.4 million in Q4 2024 and $638,000 in Q4 2023.